Treatment
Adt clinical trials
We’re tracking 66 recruiting studies that include Adt, each written for real people, not researchers, below.
Recruiting studies
- NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Phoenix, ArizonaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT07570979RecruitingPhase 1
Testing INR731 for Metastatic Prostate Cancer
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Dallas, TexasAges 18 years+ - NCT04242017RecruitingPhase 2/Phase 3
Longer hormone treatment plus salvage radiation versus shorter
This trial compares two schedules of hormone treatment (ADT) along with salvage radiation after prostate cancer surgery, to see which one controls cancer better over the long term. It may help people who have a rising PSA level after surgery but no spread found yet.
GhentAges Any age - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT05019846RecruitingPhase 3
Radiation alone versus radiation plus hormone therapy for prostate cancer
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Brescia, BSAges 18–80 - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT05346848RecruitingPhase 2
Darolutamide plus radiation for intermediate-risk prostate cancer
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
AvignonAges 18 years+ - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05790213RecruitingPhase 2
Hormone therapy plus targeted prostate treatment for intermediate cancer
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Chicago, IllinoisAges 18 years+ - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT05869682RecruitingPhase 2
Bright light therapy for fatigue and depression in prostate cancer
This Phase 2 study tests whether a “bright white light” intervention can reduce cancer-related fatigue and depression in people with advanced prostate cancer receiving hormone-based treatment. If it works, it could improve day-to-day well-being while you’re on standard cancer therapies.
Duarte, CaliforniaAges 60 years+ - NCT05873192RecruitingPhase 2
Talazoparib plus enzalutamide before prostate surgery
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Houston, TexasAges 18 years+ - NCT05879913Recruiting
Heart risk check using CT scan in men on prostate cancer therapy
This study looks at how a special CT heart scan (CCTA) can help manage heart disease risk in men with prostate cancer who are taking hormone therapy (ADT). It may help your care team better assess heart risk, especially if you also have other heart risk factors but no current heart symptoms.
Carmel, IndianaAges 40 years+ - NCT06040125Recruiting
Exercise for frailty and muscle loss in men with prostate cancer
This trial tests a supervised exercise program to see if it can reduce frailty and muscle loss in men with metastatic prostate cancer who are on hormone therapy. It may help you become stronger and feel better during treatment.
Boston, MassachusettsAges 18 years+ - NCT06111313RecruitingPhase 2
Prostate cancer trial testing targeted radiation with hormone therapy
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
Miami, FloridaAges 35–85 - NCT06163924Recruiting
Heart risk reduction in prostate cancer patients on hormone therapy
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
Hong KongAges 18–80 - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Antioch, CaliforniaAges 18 years+ - NCT06350825RecruitingPhase 3
Surgery plus hormone therapy for advanced prostate cancer
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
Nanjing, JiangsuAges 18–75 - NCT06397703RecruitingPhase 2
Testosterone Blockers and Radiation for Prostate Cancer
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
New York, New YorkAges 18 years+
Common questions
- Are there clinical trials studying Adt?
- Yes. Clin2 currently lists 66 recruiting studies that include Adt, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adt trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adt an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adt or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.